Market closed
Alector/$ALEC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alector
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Ticker
$ALEC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
241
Website
Alector Metrics
BasicAdvanced
$174M
Market cap
-
P/E ratio
-$1.70
EPS
0.66
Beta
-
Dividend rate
Price and volume
Market cap
$174M
Beta
0.66
52-week high
$8.90
52-week low
$1.74
Average daily volume
1.7M
Financial strength
Current ratio
3.293
Quick ratio
3.208
Long term debt to equity
21.827
Total debt to equity
29.125
Management effectiveness
Return on assets (TTM)
-19.25%
Return on equity (TTM)
-112.55%
Valuation
Price to revenue (TTM)
2.694
Price to book
1.47
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-0.746
Growth
Revenue change (TTM)
-36.14%
Earnings per share change (TTM)
0.28%
3-year revenue growth (CAGR)
-32.27%
3-year earnings per share growth (CAGR)
59.43%
What the Analysts think about Alector
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Alector stock.
Alector Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Alector Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Alector News
AllArticlesVideos
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Benzinga·2 weeks ago
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
GlobeNewsWire·4 weeks ago
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Alector stock?
Alector (ALEC) has a market cap of $174M as of December 21, 2024.
What is the P/E ratio for Alector stock?
The price to earnings (P/E) ratio for Alector (ALEC) stock is 0 as of December 21, 2024.
Does Alector stock pay dividends?
No, Alector (ALEC) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Alector dividend payment date?
Alector (ALEC) stock does not pay dividends to its shareholders.
What is the beta indicator for Alector?
Alector (ALEC) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.